Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00034684
Status:
COMPLETED
Last Update Posted:
2015-06-17
First Post:
2002-05-01
Brief Title:
Study of Farnesyl Protein Transferase Inhibitor FPTI in Patients With Leukemia Study P00701
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor FPTI in Patients With Leukemia
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor SCH 66336 as a single agent in patients with Advanced Myelodysplastic Syndrome Acute Myelogenous Leukemia Chronic Myelogenous Leukemia in Blast Crisis or Acute Lymphoblastic Leukemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None